Serum magnesium, mortality and disease progression in chronic kidney disease
Open Access
- 12 February 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Nephrology
- Vol. 21 (1), 1-10
- https://doi.org/10.1186/s12882-020-1713-3
Abstract
Introduction Magnesium disorders are commonly encountered in chronic kidney disease (CKD) and are typically a consequence of decreased kidney function or frequently prescribed medications such as diuretics and proton pump inhibitors. While hypomagnesemia has been linked with increased mortality, the association between elevated magnesium levels and mortality is not clearly defined. Additionally, associations between magnesium disorders, type of death, and CKD progression have not been reported. Therefore, we studied the associations between magnesium levels, CKD progression, mortality, and cause specific deaths in patients with CKD. Methods Using the Cleveland Clinic CKD registry, we identified 10,568 patients with estimated Glomerular Filtration Rate (eGFR) between 15 and 59 ml/min/1.73 m(2) in this range for a minimum of 3 months with a measured magnesium level. We categorized subjects into 3 groups based on these magnesium levels (<= 1.7, 1.7-2.6 and > 2.6 mg/dl) and applied cox regression modeling and competing risk models to identify associations with overall and cause-specific mortality. We also evaluated the association between magnesium level and slope of eGFR using mixed models. Results During a median follow-up of 3.7 years, 4656 (44%) patients died. After adjusting for relevant covariates, a magnesium level < 1.7 mg/dl (vs. 1.7-2.6 mg/dl) was associated with higher overall mortality (HR = 1.14, 95% CI: 1.04, 1.24), and with higher sub-distribution hazards for non-cardiovascular non-malignancy mortality (HR = 1.29, 95% CI: 1.12, 1.49). Magnesium levels > 2.6 mg/dl (vs. 1.7-2.6 mg/dl) was associated with a higher risk of all-cause death only (HR = 1.23, 95% CI: 1.03, 1.48). We found similar results when evaluating magnesium as a continuous measure. There were no significant differences in the slope of eGFR across all three magnesium groups (p = 0.10). Conclusions In patients with CKD stage 3 and 4, hypomagnesemia was associated with higher all-cause and non-cardiovascular non-malignancy mortality. Hypermagnesemia was associated with higher all-cause mortality. Neither hypo nor hypermagnesemia were associated with an increased risk of CKD progression.Keywords
This publication has 28 references indexed in Scilit:
- Hypomagnesemia and the Risk of Death and GFR Decline in Chronic Kidney DiseaseAmerican Journal Of Medicine, 2013
- Proton-pump inhibitor use is associated with low serum magnesium concentrationsKidney International, 2013
- Low Serum Magnesium and the Development of Atrial Fibrillation in the CommunityCirculation, 2013
- The Role of Serum Magnesium and Calcium on the Association between Adiponectin Levels and All-Cause Mortality in End-Stage Renal Disease PatientsPLOS ONE, 2012
- Relationship between Serum Magnesium Levels and Cardiovascular Events in Chronic Kidney Disease PatientsAmerican Journal of Nephrology, 2012
- Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survivalClinical Kidney Journal, 2012
- Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patientsClinical Kidney Journal, 2012
- Development and Validation of an Electronic Health Record–Based Chronic Kidney Disease RegistryClinical Journal of the American Society of Nephrology, 2011
- Molecular Determinants of Magnesium HomeostasisJournal of the American Society of Nephrology, 2008
- Serum and erythrocyte magnesium in critically ill patientsIntensive Care Medicine, 1996